Jiangsu ShengDiYa Medicine Co., Ltd.

Quick facts

Phase 2 pipeline

• Apatinib Combined With Docetaxel · Oncology
  Apatinib is a small molecule tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor 2 (VEGFR2), inhibiting angiogenesis.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Jiangsu ShengDiYa Medicine Co., Ltd. portfolio CI brief
• Jiangsu ShengDiYa Medicine Co., Ltd. pipeline updates RSS

Related

• Sector hub: All tracked pharma companies